Qiming Corporate GP VI, Ltd. sold $2.9M of ALMR (indirect holdings)

Qiming Corporate GP VI, Ltd. sold 100,117 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $29.38 ($29.34–$30.63, $2.94M total) across 8 trades on 2026-11-11. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).

Original reporting
SEC EDGAR · Qiming Corporate GP VI, Ltd., Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming GP VIII, LLC, Qiming Venture Partners VIII Investments, LLC, Qiming GP VIII-HC, LLC, Qiming Venture Partners VIII-HC, L.P.
Published Nov 14, 2026, 2:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 14, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMR
Bearish
medium confidence
Mentioned
$ALMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMRBearishLow
01

Why it matters

The reduction of a large insider stake may be interpreted as a bearish sign, but could also reflect normal portfolio management.

02

Market read

A primary insider sale filing with modest dollar size; likely limited but measurable impact on ALMR's short‑term price.

03

What to watch

Potential tax‑loss harvesting or liquidity needs for the investor may drive the sale, not company fundamentals.

Relevance 6/10Novelty 4/10Timing: post‑market today

Background

SEC Form 4 filings disclose insider transactions; this filing reports a direct market sale by a 10% owner of ALMR.

Company-level read

Ticker impact

$ALMRBearishMedium confidence
Context

Form 4 shows Qiming Corporate GP VI, Ltd. sold ~2.9M USD of ALMR shares, reducing its stake to 1.63M shares.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

The sale is sizable relative to the insider's remaining holdings and was executed at market prices, indicating possible lack of confidence.

Market effects

Minimal impact on the broader biotech sector; the transaction is company‑specific.

No significant regional effect; the filing is U.S. SEC‑based.

Limited global relevance beyond investors tracking ALMR.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal.

Key entities

  • Alamar Biosciences, Inc.

    Biotech firm listed on NASDAQ under ticker ALMR.

  • Qiming Corporate GP VI, Ltd.

    10% owner of ALMR that executed the share sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue growth of 68% YoY, with consumables up 79%. Gross margin improved to 61.5%. The company raised full-year guidance and announced partnerships with U.K. Biobank and GSK, totaling over 140,000 samples. ALMR added 35 publications, bringing the total to over 200, and strengthened its leadership team.

$ALMRMed

Alamar Biosciences (ALMR) Q3 2026 Earnings Call Transcript

Alamar Biosciences (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with gross margin at 61.5%. Net loss was $13.3M. Full-year revenue guidance raised to $121M-$123M. Company finalized large-scale studies with UK Biobank and GSK, focusing on neurodegenerative and inflammatory diseases. Cash position at $231.5M supports expansion plans. President Todd White to retire by year-end.

$ALMRMed

Alamar Biosciences Inc (ALMR) (Q3 2026) Earnings Call Highlights: Revenue Jumps 68%

Alamar Biosciences Inc (ALMR) reported Q3 2026 revenue of $33.5M, up 68% YoY, with consumables revenue representing 53% of total revenue. Gross margin reached 61.5%. Full-year guidance was raised to $121-123M. Net loss widened to $13.3M. The company secured partnerships with UK Biobank and GSK. Q4 revenue guidance implies flat sequential growth, raising concerns about near-term momentum.

$ALMRMed

Alamar Biosciences Q3 Earnings Call Highlights

Alamar Biosciences (ALMR) reported Q3 earnings, with revenue up 64% YoY. Key projects include UK Biobank work and a GSK partnership. Biopharma customers now represent 49% of revenue. Gross profit rose to $20.6M, but operating loss widened to $15.1M. The company raised its 2026 revenue guidance to $121M-$123M. ALMR plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027.

Med

Alamar Q3 2026 presentation: consumables surge, guidance raised

Alamar Biosciences reported Q3 2026 revenue of $33.5M, up 68% YoY, driven by a 79% surge in consumables sales. The company raised its full-year outlook, citing strong biopharma customer demand and research partnerships. Gross margin improved to 61.5%, but net loss widened to $13.3M due to increased operating expenses. The stock closed at $30.22, up 4.42%, before slipping in after-hours trading.

$ALMRMed

Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Alamar Biosciences, Inc. (ALMR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif. Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection o